Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
IER3
REST API REST API
Homo sapiens
IER3 is differentially expressed in 334 experiments: 130 organism parts: lung, liver, ... (128 more);, 194 disease states: normal, colorectal adenocarcinoma, ... (192 more);, 114 cell types 450 cell lines 58 compound treatments and 68 other conditions.
Synonyms PRG1, IEX-1, IEX-1L, DIF-2
Orthologs Q0P5G7_BOVIN (Bos taurus)   Ier3 (Mus musculus)   Ier3 (Rattus norvegicus)   IER3 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term protein binding, apoptosis, membrane, anti-apoptosis, positive regulation of apoptosis, anatomical structure morphogenesis, integral to membrane, regulation of apoptosis, positive regulation of protein catabolic process, negative regulation of glycolysis, negative regulation of inflammatory response, negative regulation of systemic arterial blood pressure, response to protozoan, regulation of reactive oxygen species metabolic process
UniProt Accession P46695, Q5ST79, E2QRG5
Search EB-eye ENSG00000137331
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-803, E-GEOD-6573, E-GEOD-7540, E-GEOD-3526, ... (25 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-17482, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, ... (42 experiments)

Factor Value U/D Experiments
SW480
4
E-MTAB-37, E-GEOD-18005, E-MEXP-1014, E-GEOD-2509
MCF-7
3
E-GEOD-20081, E-GEOD-19639, E-GEOD-3529
BT474
2
E-MEXP-440, E-MTAB-62
CCRFCEM
2
E-MTAB-37, E-GEOD-24147
DU145
2
E-GEOD-17482, E-GEOD-20089
PC3
2
E-GEOD-5258, E-GEOD-14464
444 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-GEOD-20677, E-GEOD-2822, ... (56 experiments)

Factor Value U/D Experiments
macrophage
1
3
E-GEOD-8286, E-GEOD-22373, E-GEOD-5099, E-GEOD-3982
721 B lymphoblast
2
E-AFMX-5, E-TABM-145
CD33+ myeloid
2
E-AFMX-5, E-TABM-145
embryonic stem cell
2
E-MEXP-930, E-GEOD-2248
endothelial cell
2
E-GEOD-3920, E-GEOD-19240
cardiac myocyte
1
2
E-AFMX-5, E-MTAB-25, E-TABM-145
108 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-2466, E-TABM-15, E-MTAB-62, E-MTAB-680, ... (58 experiments)

Factor Value U/D Experiments
malignant peripheral nerve sheath tumor
2
E-MTAB-62, E-GEOD-6481
acute promyelocytic leukemia
2
E-MTAB-62, E-GEOD-995
adrenocortical carcinoma
2
E-TABM-311, E-GEOD-10927
glioblastoma
2
E-MTAB-37, E-MTAB-62
lung adenocarcinoma
2
E-MTAB-37, E-MTAB-62
obesity
2
E-MTAB-62, E-GEOD-2508
188 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-5741, E-TABM-782, E-GEOD-3720, E-TABM-868, ... (34 experiments)

Factor Value U/D Experiments
lipopolysaccharide
3
E-TABM-868, E-GEOD-3720, E-MEXP-1958
2,3-dimethoxy-1,4-naphthoquinone
1
E-GEOD-6907
vanadium
1
E-GEOD-2111
sapphyrin PCI-2053
1
E-GEOD-6400
5-aza-2'-deoxycytidine
2
1
E-MEXP-1269
CNOT7+CNOT8
1
E-MEXP-2218
52 more value(s).


Age at onset

studied in E-GEOD-21521

Factor Value U/D Experiments
not specified
1
E-GEOD-21521
LT6
1
E-GEOD-21521


Agent
studied in E-GEOD-19519

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Chromosomal aberration
studied in E-GEOD-1729

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-2171, ... (9 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-1140, E-MEXP-1251, E-GEOD-21374, ... (9 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-1614, E-GEOD-20033, E-MEXP-2359, E-MEXP-958, E-MTAB-62 ... (5 experiments)

Disease staging
studied in E-GEOD-89, E-GEOD-1323, E-GEOD-19743, E-GEOD-3325, E-MTAB-69, ... (10 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720, E-GEOD-4086

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-7011, E-MTAB-73, E-GEOD-7578, E-GEOD-20847, E-MTAB-108, ... (6 experiments)

Genotype
studied in E-GEOD-1045, E-MEXP-1996, E-GEOD-17476, E-GEOD-2466, E-GEOD-22593, ... (16 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-13073, E-MEXP-1220, E-GEOD-5681, E-TABM-127, E-GEOD-20540, ... (12 experiments)

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-MEXP-2069, E-GEOD-1926, ... (32 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12108, E-GEOD-6802, E-GEOD-923

Injury
studied in E-GEOD-19743

Irradiate
studied in E-TABM-321

Ki67 ihc
studied in E-GEOD-21653

Light
studied in E-GEOD-1725

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-TABM-84

P53 ihc
studied in E-GEOD-21653

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-7819, E-GEOD-22152, E-GEOD-21750, E-GEOD-1657, E-GEOD-1460, ... (9 experiments)

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-21837, E-GEOD-19445, E-GEOD-1343, E-GEOD-20037 ... (5 experiments)

Replicate
studied in E-GEOD-18791, E-GEOD-10896

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-2115, E-GEOD-1703, E-MEXP-1509, E-MEXP-101, E-GEOD-3697, ... (7 experiments)

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-MEXP-70, E-GEOD-17400, E-GEOD-18995 ... (5 experiments)

Sex
studied in E-GEOD-2466, E-GEOD-7307

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-13909, E-GEOD-20114, E-GEOD-12710

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Treatment
studied in E-GEOD-22369, E-GEOD-22368, E-GEOD-16193, E-GEOD-16837, E-MEXP-973, ... (8 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-1561, E-TABM-147

Processing time: 0.287 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM